CAR T-Cell Therapy Shows Superior PFS in R/R Multiple Myeloma Nalley, Catlin Nalley, Catlin Less Oncology Times. 45(8):14-15, April 20, 2023. Favorite PDF Permissions Free CME Test
In-House Technology Used to Expedite Delivery of CAR-T Therapy Froelich, Warren Froelich, Warren Less Oncology Times. 45(8):1,10, April 20, 2023. Favorite PDF Permissions Free
Triple-Drug Therapy for Post-Transplant Multiple Myeloma Less Oncology Times. 45(5):27, March 5, 2023. Favorite PDF Permissions Free
Survival Impact & Prognostic Value of Sarcopenia in Multiple Myeloma Holt, Chuck Holt, Chuck Less Oncology Times. 45(5):17, March 5, 2023. Favorite PDF Permissions Free
Teclistamab-cqyv (Tecvayli™) Minor, Chelsea Minor, Chelsea Less Oncology Times. 45(4):10, February 20, 2023. Favorite PDF Permissions Free
Treatments for Multiple Myeloma in the Upfront & Relapsed Settings Holt, Chuck Holt, Chuck Less Oncology Times. 45(3):25, February 5, 2023. Favorite PDF Permissions Free
3 QUESTIONS ON . . . Whether Leukemia & Myeloma Trials Represent Patients at Risk: With Jorge Cortes, MD, Director of the Georgia Cancer Center at Augusta University DiGiulio, Sarah DiGiulio, Sarah Less Oncology Times. 45(2):26, January 20, 2023. Favorite PDF Permissions Free
GPRC5D-Targeted CAR T-Cell Therapy Effective in Advanced Multiple Myeloma Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 44(22):1,19, November 20, 2022. Favorite PDF Permissions Free
Addressing Disparities in CAR T-Cell Therapy Trials Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 44(14):1,12, July 20, 2022. Favorite PDF Permissions Free
Daratumumab in Combination for Transplant-Ineligible Newly Diagnosed Multiple Myeloma Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 43(23):1,21, December 5, 2021. Favorite PDF Permissions Free
Recommendations Target Racial Disparities in Multiple Myeloma Trials Holt, Chuck Holt, Chuck Less Oncology Times. 43(11):18,20, June 5, 2021. Favorite PDF Permissions Free
Study Highlights Need to Protect Multiple Myeloma Patients From Infection Nalley, Catlin Nalley, Catlin Less Oncology Times. 43(6):24,25,26,27,38, March 20, 2021. Favorite PDF Permissions Free
Belantamab Mafodotin-Blmf (Blenrep) Minor, Chelsea Minor, Chelsea Less Oncology Times. 43(4):15, February 20, 2021. Favorite PDF Permissions Free
Adjuvant Immunotherapy Offers Survival Benefit Among Some Melanoma Patients Nalley, Catlin Nalley, Catlin Less Oncology Times. 42(15):36, August 5, 2020. Favorite PDF Permissions Free
STORM Trial Advances Selinexor + Dexamethasone for Multiple Myeloma Holt, Chuck Holt, Chuck Less Oncology Times. 42(14):1,8,19, July 20, 2020. Favorite PDF Permissions Free
STORM Trial Advances Selinexor + Dexamethasone for Multiple Myeloma Holt, Chuck Holt, Chuck Less Oncology Times. 42(14):1,8,19, July 20, 2020. Favorite PDF Permissions Free
Reversing Treatment Resistance in Advanced Multiple Myeloma Less Oncology Times. 42(8):36, April 20, 2020. Favorite PDF Permissions Free
Advances in Dendritic Cell-Based Therapies for Hematologic Malignancies Simoneaux, Richard Simoneaux, Richard Less Oncology Times. 42(8):1,20-21, April 20, 2020. Favorite PDF Permissions Free
Genetic Test Could Target High-Risk Bone Marrow Cancer Patients Less Oncology Times. 42(7):1,11, April 5, 2020. Favorite PDF Permissions Free
New CAR-T Target Yields Promising Results for Multiple Myeloma Less Oncology Times. 42(5):32, March 5, 2020. Favorite PDF Permissions Free
Age & Transplantation Benefits in Multiple Myeloma Patients Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 42(3):38, February 5, 2020. Favorite PDF Permissions Free
An Addition to BCMA-Targeted CAR-T Cells in Multiple Myeloma Simoneaux, Richard Simoneaux, Richard Less Oncology Times. 42(3):37, February 5, 2020. Favorite PDF Permissions Free
BCMA-Targeted Immunotherapy Can Lead to Durable Responses In Multiple Myeloma Less Oncology Times. 42(2):21, January 20, 2020. Favorite PDF Permissions Free
Researcher Urges Caution in Use of Surrogate Endpoints in Clinical Trials Simoneaux, Richard Simoneaux, Richard Less Oncology Times. 41(20):1,9, October 20, 2019. Favorite PDF Permissions Free
Examining the Clinical Heterogeneity of Smoldering Multiple Myeloma Binder, Adam; Porcu, Pierluigi Binder, Adam; Porcu, Pierluigi Less Oncology Times. 40(20):1,8,9,17, October 20, 2018. Favorite PDF Permissions Free
Artificial Intelligence to Identify Personalized Drug Combos in Myeloma Less Oncology Times. 40(17):41, September 5, 2018. Favorite PDF Permissions Free
RNA & DNA-Sequencing for Multiple Myeloma Less Oncology Times. 40(17):30-31, September 5, 2018. Favorite PDF Permissions Free
Combination Therapy Shows Synergistic Effect in Myeloma Treatment Kang, Yubin; Sundaramoorthy, Pasupathi Kang, Yubin; Sundaramoorthy, Pasupathi Less Oncology Times. 40(16):1,6,8, August 20, 2018. Favorite PDF Permissions Free
New Therapies Target the Achilles Heels of Multiple Myeloma Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 40(15):33, August 5, 2018. Favorite PDF Permissions Free
Looking at Urine & Blood May Aid in Diagnosis of Myeloma Less Oncology Times. 40(15):23, August 5, 2018. Favorite PDF Permissions Free
The Role of Novel Antibody Strategies in Relapsed/Refractory Multiple Myeloma Nalley, Catlin Nalley, Catlin Less Oncology Times. 40(15):1,12, August 5, 2018. Favorite PDF Permissions Free
The Role of Genetic Mutations in Multiple Myeloma Outcomes Nalley, Catlin Nalley, Catlin Less Oncology Times. 40(10):24, May 20, 2018. Favorite PDF Permissions Free
Matching Blood Biopsies to Bone Marrow Tests in Multiple Myeloma Less Oncology Times. 40(10):28-29, May 20, 2018. Favorite PDF Permissions Free
Prevalence of Cognitive Decline Among Elderly Patients With Hematologic Cancers Nalley, Catlin Nalley, Catlin Less Oncology Times. 40(7):1,7, April 5, 2018. Favorite PDF Permissions Free
Lenalidomide/Dexamethasone With or Without Carfilzomib in Multiple Myeloma Simoneaux, Richard Simoneaux, Richard Less Oncology Times. 40(6):1,9, March 20, 2018. Favorite PDF Permissions Free
Risk of MGUS Progression to Multiple Myeloma Persists Throughout Life May, Brandon May, Brandon Less Oncology Times. 40(5):28-29, March 5, 2018. Favorite PDF Permissions Free
First-Line Daratumumab Benefit in Multiple Myeloma Goodwin, Peter M. Goodwin, Peter M. Less Oncology Times. 40(3):34, February 5, 2018. Favorite PDF Permissions Free
Single-Cell RNA Sequencing Could Improve Myeloma Treatment Nalley, Catlin Nalley, Catlin Less Oncology Times. 40(3):31, February 5, 2018. Favorite PDF Permissions Free
Debate: Should All Eligible Myeloma Patients Receive Upfront Transplant? Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 39(24):53-61, December 25, 2017. Favorite PDF Permissions Free
Daratumumab Combo for Relapsed/Refractory Multiple Myeloma Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 39(24):52, December 25, 2017. Favorite PDF Permissions Free
ADAR1 Enzyme Associated With Reduced Survival in Multiple Myeloma Less Oncology Times. 39(24):9, December 25, 2017. Favorite PDF Permissions Free
Debate: Best Initial Therapy for Young, Fit Multiple Myeloma Patients Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 39(23):55-56, December 10, 2017. Favorite PDF Permissions Free
Variety of Immunotherapies Hold Promise to Treat Multiple Myeloma Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 39(23):54, December 10, 2017. Favorite PDF Permissions Free
Debate: What Role Do Transplants Play in the Treatment of Myeloma? Nalley, Catlin Nalley, Catlin Less Oncology Times. 39(23):36, December 10, 2017. Favorite PDF Permissions Free
Carfilzomib & Dexamethasone Beneficial in Multiple Myeloma Less Oncology Times. 39(18):9, September 25, 2017. Favorite PDF Permissions Free
Confusion of Cancer's Status After Stem Cell Transplant for Multiple Myeloma Less Oncology Times. 39(17):1,14, September 10, 2017. Favorite PDF Permissions Free
Daratumumab Combination Therapy Approved for Multiple Myeloma Less Oncology Times. 39(13):57, July 10, 2017. Favorite PDF Permissions Free
CAR T-Cell Therapy Leads to Durable Remissions in Multiple Myeloma Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 39(13):30, July 10, 2017. Favorite PDF Permissions Free
Salvage Therapy for Myeloma Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 39(12):19,38, June 25, 2017. Favorite PDF Permissions Free
Stem-Cell Transplant Plus Novel Drug Combo Lengthens Control of Myeloma Less Oncology Times. 39(9):46, May 10, 2017. Favorite PDF Permissions Free
Promising New Therapies on Horizon for Multiple Myeloma Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 39(9):1,10, May 10, 2017. Favorite PDF Permissions Free
No Need for Triple Therapy or Second Transplant for Multiple Myeloma Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 39(3):38, February 10, 2017. Favorite PDF Permissions Free
Multiple Myeloma: An ASH 2016 Overview Vij, Ravi Vij, Ravi Less Oncology Times. 39(3):1,10,11,12,13,15, February 10, 2017. Favorite PDF Permissions Free CME Test
Daratumumab Approved for New Use in Multiple Myeloma Less Oncology Times. 39(2):23-24, January 25, 2017. Favorite PDF Permissions Free
Manuscripts in Myeloma 2016 Vij, Ravi Vij, Ravi Less Oncology Times. 39(1):1,7-8, January 10, 2017. Favorite PDF Permissions Free
Triplet Therapy in Relapsed or Refractory Multiple Myeloma Simoneaux, Richard Simoneaux, Richard Less Oncology Times. 38(22):17,24-25, November 25, 2016. Favorite PDF Permissions Free
As BMI Increases, So Does Multiple Myeloma Less Oncology Times. 38(16):1,22, August 25, 2016. Favorite PDF Permissions Free
The Addition of Panobinostat for Patients With Multiple Myeloma Kim, Meeri Kim, Meeri Less Oncology Times. 38(11):1,8, June 10, 2016. Favorite PDF Permissions Free
Debate: No One-Size-Fits-All in Multiple Myeloma Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 38(10):29-30, May 25, 2016. Favorite PDF Permissions Free
Invariant Natural Killer T Cells & Allogeneic Stem Cell Transplantation Kim, Meeri Kim, Meeri Less Oncology Times. 38(10):1,22-23, May 25, 2016. Favorite PDF Permissions Free
FDA Approves Kyprolis Combo Therapy for Relapsed/Refractory Multiple Myeloma Less Oncology Times. 38(5):20, March 10, 2016. Favorite PDF Permissions Free
POINT-COUNTERPOINT: HDAC Inhibitors Hit a Single, Not a Home Run, Against Myeloma Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 38(4):34-35, February 25, 2016. Favorite PDF Permissions Free
POINT-COUNTERPOINT: To Maintain or Not to Maintain in Myeloma Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 38(4):10-12, February 25, 2016. Favorite PDF Permissions Free
Paradigm Shift in Myeloma Care Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 38(4):1,5-5, February 25, 2016. Favorite PDF Permissions Free
Stem Cell Transplant in Myeloma: Necessity or Choice? Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 38(3):1,7-9, February 10, 2016. Favorite PDF Permissions Free
Best Myeloma Abstracts from ASH 2015 Vij, Ravi Vij, Ravi Less Oncology Times. 38(2):3-6, January 25, 2016. Favorite PDF Permissions Free
FDA Approves Empliciti & Ninlaro for Multiple Myeloma Less Oncology Times. 38(1):8, January 10, 2016. Favorite PDF Permissions Free
Myeloma: How to Fit the Three New Drugs into Clinical Practice: NEW: Earn CME by Reading This Article! Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 38(1):24-25, January 10, 2016. Favorite PDF Permissions Free
Best Multiple Myeloma Research, 2015 Vij, Ravi Vij, Ravi Less Oncology Times. 38(1):1,13-14, January 10, 2016. Favorite PDF Permissions Free
FDA Approves Darzalex for Previously Treated Multiple Myeloma Less Oncology Times. 37(24):15, December 25, 2015. Favorite PDF Permissions Free
Multiple Myeloma: Excitement about Monoclonal Antibodies Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 37(23):1,19-20, December 10, 2015. Favorite PDF Permissions Free
FDA Priority Review to CLL and Myeloma Drugs Less Oncology Times. 37(22):62, November 25, 2015. Favorite PDF Permissions Free
Myeloma-Related Renal Failure on the Decline Less Oncology Times. 37(22):21, November 25, 2015. Favorite PDF Permissions Free
Priority Review to Two Drugs for Multiple Myeloma Less Oncology Times. 37(20):3, October 25, 2015. Favorite PDF Permissions Free
Daratumumab Receives FDA Priority Review for Double-Refractory Myeloma Less Oncology Times. 37(19):29, October 10, 2015. Favorite PDF Permissions Free
Myeloma Exome Analysis Uncovers Clinical Insights Samson, Kurt Samson, Kurt Less Oncology Times. 37(19):1,18-19, October 10, 2015. Favorite PDF Permissions Free
First Report of Success of T-Cell Therapy in Myeloma Less Oncology Times. 37(16):39, August 25, 2015. Favorite PDF Permissions Free
POINT-COUNTERPOINT: Best Maintenance Therapy for Patients with Newly Diagnosed Multiple Myeloma Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 37(16):40-42, August 25, 2015. Favorite PDF Permissions Free
Refractory Myeloma: A Monoclonal Antibody for First Time Has Single-Agent Activity Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 37(13):8-9, July 10, 2015. Favorite PDF Permissions Free
First Monoclonal Antibody for Myeloma Shows Increases in PFS and Overall Response Carlson, Robert H. Carlson, Robert H. Less Oncology Times. 37(11):37-38, June 10, 2015. Favorite PDF Permissions Free
Myeloma Debate: Should Consolidation Therapy & MRD Testing be Used for Monitoring & Treatment? Fuerst, Mark Fuerst, Mark Less Oncology Times. 37(11):1,36-37, June 10, 2015. Favorite PDF Permissions Free
Myeloma: New Scoring System Better IDs Frail vs. Fit Elderly Patients—Opens Door to Improved Decisions about Treatment Options Samson, Kurt Samson, Kurt Less Oncology Times. 37(10):40-41, May 25, 2015. Favorite PDF Permissions Free
Cancer-Related Crowdsourcing and Crowdfunding Move beyond the Basics—with Many Active Projects Ongoing in Myeloma Butcher, Lola Butcher, Lola Less Oncology Times. 37(10):18-20, May 25, 2015. Favorite PDF Permissions Free
Warning that Patients Having Hematopoietic Stem Cell Transplants Appear to Have More Fractures Lindsey, Heather Lindsey, Heather Less Oncology Times. 37(9):1,26-27, May 10, 2015. Favorite PDF Permissions Free
FDA Grants Priority Review to Kyprolis for Multiple Myeloma Less Oncology Times. 37(8):8, April 25, 2015. Favorite PDF Permissions Free
New Data Provoke Screening Debate about MGUS and Multiple Myeloma Fuerst, Mark Fuerst, Mark Less Oncology Times. 37(8):1,27-29, April 25, 2015. Favorite PDF Permissions Free
iPad Extras: Audio Reports from the ASH Annual Meeting Less Oncology Times. 37(4):43, February 25, 2015. Favorite PDF Permissions Free
High-Risk Smoldering Myeloma: To Treat or Not to Treat Still a Question Fuerst, Mark Fuerst, Mark Less Oncology Times. 37(3):24-26, February 10, 2015. Favorite PDF Permissions Free
Key Myeloma Takeaways from ASH 2014 Vij, Ravi Vij, Ravi Less Oncology Times. 37(3):1,7-9, February 10, 2015. Favorite PDF Permissions Free
Myeloma: Should Complete Remission, However Strictly Defined, Be the Goal for All Patients? Fuerst, Mark Fuerst, Mark Less Oncology Times. 37(2):19-21, January 25, 2015. Favorite PDF Permissions Free
Multiple Myeloma: Oral Proteosome Inhibitor Ixazomib Moves from Induction to Maintenance Carlson, Robert H. Carlson, Robert H. Less Oncology Times. 37(2):9, January 25, 2015. Favorite PDF Permissions Free
Anti-CD38 Monoclonal Antibodies Called Next ‘Blockbuster’ Drug Class for Myeloma Carlson, Robert H. Carlson, Robert H. Less Oncology Times. 37(2):13-15, January 25, 2015. Favorite PDF Permissions Free
Crowds ASPIRE to Hear Myeloma Report Carlson, Robert H. Carlson, Robert H. Less Oncology Times. 37(1):38-39, January 10, 2015. Favorite PDF Permissions Free
Best Myeloma Research of 2014 Vij, Ravi Vij, Ravi Less Oncology Times. 36(24):1,13-15, December 25, 2014. Favorite PDF Permissions Free
‘Missing Piece of Myeloma Puzzle’ Defined Kim, Meeri Kim, Meeri Less Oncology Times. 36(23):1,82-83, December 10, 2014. Favorite PDF Permissions Free
AACR Conference Highlights Promising Early Research on Blood Malignancies Samson, Kurt Samson, Kurt Less Oncology Times. 36(20):57-61, October 25, 2014. Favorite PDF Permissions Free
Debating Upfront Transplant in Multiple Myeloma Carlson, Robert H. Carlson, Robert H. Less Oncology Times. 36(20):1,19-22, October 25, 2014. Favorite PDF Permissions Free
Multiple Myeloma: Panobinostat in Combination with Bortezomib and Dexamethasone Extends Progression-Free Survival in Patients Who Have Disease Relapse Fuerst, Mark Fuerst, Mark Less Oncology Times. 36(17):42-44, September 10, 2014. Favorite PDF Permissions Free
Hematological Malignancy Takeaways from ASCO 2014 Vij, Ravi Vij, Ravi Less Oncology Times. 36(14):1,14-16, July 25, 2014. Favorite PDF Permissions Free
Myeloma: Debating the Optimal Approach for Patients with Relapsed/Refractory Disease Fuerst, Mark Fuerst, Mark Less Oncology Times. 36(10):80-81, May 25, 2014. Favorite PDF Permissions Free
